Table 1 Patient demographics and characteristics for all GEP-NET patients receiving [⁶⁸Ga]Ga-DOTATATE or [⁶⁸Ga]Ga-HA-DOTATATE

Sex

 Male

14 (36%)

31 (53%)

0.356

 Female

25 (64%)

28 (47%)

Age (years)

62 ± 11.6 (39–84)

62 ± 10.8 (40–82)

0.895

Weight (kg)

77.5 ± 14.7 (53.0–117)

72.0 ± 13.8 (44.0–113)

0.0697

Height (cm)

171 ± 7.62 (157–185)

173 ± 8.25 (158–192)

0.290

GFR (Cockcroft Gault, mL/min)

90.7 ± 26.9 (33.8–147)

82.3 ± 25.2 (35.8–183)

0.149

Peptide amount administered (µg)

13.1 ± 2.18 (7.16–16.6)

6.06 ± 2.26 (2.43–11.1)

 < 0.001

Radioactivity administered (MBq)

85.8 ± 16.0 (50.3–133)

85.7 ± 14.1 (43.8–106)

0.981

Injection-acquisition interval (min)

44 ± 6 (34–55)

44 ± 6 (29–55)

0.952

Primary tumor

 Pancreas

9 (23%)

17 (29%)

0.815

 Small intestine

23 (59%)

34 (58%)

 Colon

4 (10%)

4 (7%)

 Rectum

–

1 (2%)

 Stomach

3 (8%)

3 (5%)

Tumor grade

 1

21 (54%)

20 (34%)

0.103

 2

12 (31%)

27 (46%)

 Unknown

6 (15%)

12 (20%)

SUV_max

 Aorta

1.81 ± 0.635 (0.93–3.26)

1.25 ± 0.408 (0.62–2.36)

 < 0.001

 Spleen

18.2 ± 6.14 (7.07–31.5)

27.7 ± 9.04 (12.6–52.8)

 < 0.001

 Liver

7.47 ± 2.83 (2.81–17.7)

11.3 ± 2.92 (5.23–18.4)

 < 0.001

 Thyroid

3.47 ± 1.45 (1.38–7.85)

5.30 ± 2.17 (2.17–14.9)

 < 0.001

 Primary tumor

24.1 ± 15.3 (6.33–63.5)

29.9 ± 18.6 (8.58–74.9)

0.291

 Liver metastases

25.1 ± 12.4 (6.97–53.7)

33.1 ± 13.2 (13.8–79.8)

0.014

 Other metastases

15.5 ± 13.3 (2.12–83.4)

21.3 ± 15.8 (2.71–75.7)

0.020

SUV_peak

 Aorta

1.30 ± 0.425 (0.64–2.33)

0.918 ± 0.278 (0.52–1.75)

 < 0.001

 Spleen

16.4 ± 5.52 (6.34–26.3)

25.2 ± 7.91 (11.5–41.2)

 < 0.001

 Liver

6.07 ± 2.19 (2.45–12.9)

9.86 ± 2.63 (4.44–16.7)

 < 0.001

 Thyroid

2.52 ± 1.18 (0.80–6.50)

3.81 ± 1.50 (1.41–9.54)

 < 0.001

 Primary tumor

18.0 ± 13.1 (4.74–53.7)

20.1 ± 11.9 (6.21–48.7)

0.509

 Liver metastases

19.6 ± 10.3 (6.18–47.2)

25.4 ± 10.1 (11.5–54.6)

0.017

 Other metastases

9.67 ± 8.44 (1.06–44.5)

14.6 ± 11.5 (1.53–51.5)

0.007

Peptide accumulation (µg/L)

 Spleen

2.81 ± 1.10 (1.06–4.98)

2.14 ± 1.01 (0.66–5.29)

0.002

 Primary tumor

2.99 ± 2.50 (0.77–8.58)

1.81 ± 1.64 (0.31–7.67)

0.092

 Liver metastases

3.48 ± 2.00 (0.76–8.39)

2.30 ± 1.09 (0.85–4.88)

0.009

 Other metastases

1.34 ± 1.13 (0.19–6.36)

1.05 ± 0.90 (0.11–3.59)

0.067